Generative AI for Health Technology Assessment: Opportunities, Challenges, and Policy Considerations

Overview

• This review explores the transformative potential of generative Artificial Intelligence (AI) and foundation models, including large language models (LLMs), for health technology assessment (HTA).
• The paper examines four critical areas where generative AI can have a significant impact: evidence synthesis, evidence generation, clinical trials, and economic modeling.
• Despite the promise of these technologies, they are still evolving, and careful evaluation of their applications in HTA is required to ensure responsible use and implementation.

Plain English Explanation

Generative AI, including large language models, has the potential to revolutionize how we conduct health technology assessment (HTA) - the process of evaluating the clinical and economic impact of new medical technologies.

In the area of evidence synthesis, generative AI can help automate the tedious process of literature reviews and meta-analyses. These models can suggest search terms, screen abstracts, and extract relevant data with a high degree of accuracy, significantly speeding up the process.

When it comes to evidence generation, generative AI can also help analyze the growing amount of real-world data, such as clinical notes and medical images. This can enhance the speed and quality of real-world evidence, which is crucial for understanding the actual impact of medical technologies in everyday clinical practice.

In the realm of clinical trials, generative AI can be used to optimize trial design, improve patient matching, and manage trial data more efficiently. This can lead to faster, more effective clinical research.

Finally, in the area of economic modeling, generative AI can assist in the development of health economic models, from the initial conceptualization to the final validation. This can streamline the overall HTA process and help decision-makers better understand the cost-effectiveness of new medical technologies.

While these technologies hold great promise, they are still in their early stages. Continued careful evaluation is necessary to ensure their responsible use and implementation, addressing issues related to scientific validity, bias, and ethical implications.

Technical Explanation

The review explores the potential of generative AI, including large language models (LLMs), to transform four critical areas of health technology assessment (HTA):

1. Evidence Synthesis: Generative AI has the ability to assist in automating literature reviews and meta-analyses. These models can propose search terms, screen abstracts, and extract data with notable accuracy, significantly streamlining the process.

2. Evidence Generation: Generative AI can facilitate the analysis of large collections of real-world data (RWD), including unstructured clinical notes and medical imaging. This can enhance the speed and quality of real-world evidence (RWE) generation, providing a more comprehensive understanding of the actual impact of medical technologies.

3. Clinical Trials: Generative AI can be used to optimize clinical trial design, improve patient matching, and manage trial data more efficiently. This can lead to faster and more effective clinical research.

4. Economic Modeling: Generative AI can aid in the development of health economic models, from the initial conceptualization to the final validation. This can help streamline the overall HTA process and provide decision-makers with better insights into the cost-effectiveness of new medical technologies.

While these technologies hold great promise, they are still nascent and require continued careful evaluation in their applications to HTA. Developers and users of research incorporating these tools should familiarize themselves with their current limitations, including issues related to scientific validity, risk of bias, and ethical implications.

Critical Analysis

The review acknowledges the transformative potential of generative AI and foundation models, such as large language models (LLMs), in the context of health technology assessment (HTA). However, it also highlights the need for continued careful evaluation and responsible implementation of these technologies.

One key limitation mentioned is the evolving nature of these tools, as they are still rapidly improving. This means that any applications or insights derived from them may be subject to change as the technology advances. The review emphasizes the importance of continuously monitoring and evaluating the performance, accuracy, and reliability of these models in the specific context of HTA.

Additionally, the review raises concerns about the potential for bias and scientific validity issues when using generative AI in HTA. These models can be influenced by the data they are trained on, which may not be representative of the full diversity of the population or clinical contexts. Developers and users need to be mindful of these limitations and take steps to mitigate them, such as thorough validation and testing.

The review also highlights the need to consider the ethical implications of using generative AI in HTA. These technologies have the potential to impact decision-making processes, which can have significant consequences for patients and healthcare systems. It is crucial to ensure that their use is transparent, accountable, and aligned with principles of equity and fairness.

Overall, the review provides a balanced perspective, acknowledging the transformative potential of generative AI while also emphasizing the importance of responsible development, implementation, and ongoing evaluation to address the current limitations and ethical concerns.

Conclusion

This review highlights the transformative potential of generative Artificial Intelligence (AI) and foundation models, including large language models (LLMs), for health technology assessment (HTA). The paper explores their applications in four critical areas: evidence synthesis, evidence generation, clinical trials, and economic modeling.

Generative AI has the ability to automate and streamline various HTA processes, from literature reviews and meta-analyses to the analysis of real-world data and the development of health economic models. These technologies hold great promise in enhancing the speed, accuracy, and efficiency of HTA, which can ultimately lead to faster and more informed decision-making in healthcare.

However, as these technologies are still evolving, the review emphasizes the need for continued careful evaluation and responsible implementation. Developers and users of research incorporating these tools must be mindful of the current limitations, including issues related to scientific validity, risk of bias, and ethical implications.

By addressing these challenges and integrating generative AI into HTA workflows with appropriate human oversight, the healthcare sector can harness the power of these transformative technologies to improve patient outcomes, optimize resource allocation, and drive innovation in the field of medical technology assessment.